Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Standard-of-care therapy for previously untreated advanced non–small-cell lung cancer (NSCLC) without treatable driver mutations includes platinum-based chemotherapy and pembrolizumab for patients with a high level (≥50%) of tumor programmed death ligand 1 (PD-L1) expression. There remains a need…

https://ift.tt/2HnaU0u